Selecta Biosciences, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SELB research report →
Companyselectabio.com
Selecta Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in preclinical stage to improve the treatment of methylmalonic acidemia.
- CEO
- Carsten Brunn
- IPO
- 2016
- Employees
- 64
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $135.20M
- P/E
- -0.16
- P/S
- 76.17
- P/B
- -0.16
- EV/EBITDA
- -0.81
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- -8550.65%
- ROE
- 194.13%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $2.80M · -92.81%
- Net Income
- $-130,302,000 · -68.30%
- EPS
- $-5.02 · -904.00%
- Op Income
- $0
- FCF YoY
- -142.30%
Performance & Tape
- 52W High
- $1.99
- 52W Low
- $0.79
- 50D MA
- $1.10
- 200D MA
- $1.19
- Beta
- 0.83
- Avg Volume
- 634.42K
Get TickerSpark's AI analysis on SELB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 24 | Singer Michael | other | 178,000 |
| Jan 2, 24 | Singer Michael | other | 228,000 |
| Dec 22, 23 | Singer Michael | other | 3,000 |
| Jan 2, 24 | Davis Blaine | other | 3,110,000 |
| Jan 2, 24 | Davis Blaine | other | 2,424,000 |
| Jan 2, 24 | Jewell Christopher M | other | 998,000 |
| Jan 2, 24 | Jewell Christopher M | other | 778,200 |
| Jan 2, 24 | Brunn Carsten | other | 5,971,000 |
| Jan 2, 24 | Brunn Carsten | other | 4,654,100 |
| Jan 2, 24 | Sallin Aymeric | other | 228,000 |
Our SELB Coverage
We haven't published any research on SELB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SELB Report →